30 October 2025
Scancell Holdings plc
("Scancell" or the "Company")
Result of Annual General Meeting
Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies to treat cancer, announces that all resolutions proposed at the Annual General Meeting held today were duly passed.
-ENDS-
Scancell (LSE:SCLP; www.scancell.co.uk) is a clinical stage biotechnology company developing targeted off-the-shelf active immunotherapies, to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, the lead product from their DNA ImmunoBody® platform has demonstrated safe, durable and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the lead peptide immunotherapy from their Moditope® platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, Scancell's wholly owned subsidiary, GlyMab Therapeutics Ltd., has been established with the intention to hold and develop an exciting early-stage pipeline of high affinity GlyMab® antibodies targeting tumour specific glycans, two of which already have been licensed and are being developed by Genmab A/S, an international biotechnology company and global leader in the antibody therapeutics space.
For more information please contact:
|
Scancell Holdings plc |
+44 (0) 20 3709 5700 |
|
Phil L'Huillier, CEO |
|
|
Sath Nirmalananthan, CFO |
|
|
Panmure Liberum (Nominated Adviser and Joint Broker) |
+44 (0) 20 7886 2500 |
|
Emma Earl, Will Goode, Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking) |
|
|
WG Partners LLP (Joint Broker) David Wilson, Claes Spang |
+44 (0) 20 3705 9330 |
|
Investor and media relations Mary-Ann Chang |
+44 (0) 20 7483 284853 MaryAnnChang@scancell.co.uk |